NovaQuest Capital Management
NovaQuest Capital Management is a life science investment firm specializing in biopharmaceuticals, located in North Carolina’s Research Triangle. Founded in 2010, the firm focuses on promoting the late-stage development of life-saving drugs to reduce healthcare costs, address unmet medical needs, improve safety, and enhance quality of life. With a unique global platform, NovaQuest provides tailored capital solutions to fund innovation in biopharmaceutical development and invests in healthcare companies with products and technologies aimed at improving human and animal health.
NovaQuest Capital Management
4208 Six Forks Road, Suite 920, Raleigh, NC 27609
What We Do
NovaQuest provides at-risk, non-dilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies.
NovaQuest offers structured finance solutions for Phase III pharmaceutical partners, supporting the completion of full development programs.
Industry Focus
Investment Stage
Portfolio
Aceragen launched with the acquisition of Enzyvant’s investigational therapy for Farber Disease and $35 million product financing with NovaQuest.
#Biopharmaceuticals
Argenta entered a $30 million product financing agreement with NovaQuest to accelerate new veterinary product development.
#Animal Health
Cerevel announced a strategic $125 million non-dilutive financing transaction for Tavapadon with NovaQuest and Bain Capital.
#Neuroscience
FibroGen announced a $50 million royalty monetization financing with NovaQuest to support strategic priorities.
#Biopharmaceuticals
Grünenthal and NovaQuest entered an agreement to advance the resiniferatoxin global Phase III program in osteoarthritis.
#Pain Management
Hansa Biopharma secured $70 million in non-dilutive financing from NovaQuest to support the development of its antibody-cleaving enzyme technology platform.
#Biopharmaceuticals
NovaQuest continues as a minority investor in Clinical Ink, a global clinical trial technology company.
#Clinical Trial Technology
Key People
Head of Investor Relations